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INTRODUCTION
Aripiprazole, a relatively new atypical antipsychotic, shares 
some advantages with other atypical antipsychotics, i.e., effec-
tiveness on both positive and negative symptoms of schizo-
phrenia. Moreover, some studies have shown additional ben-
efits for aripiprazole, despite a controversy about the specificity 
of the benefits. For example, aripiprazole has a better efficacy 
in reducing deficit symptoms compared to other antipsycho-
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tics such as olanzapine, quetiapine or risperidone.1 Patients 
who switched from either olanzapine or risperidone to aripi-
prazole manifested improvements in subjective well-being.2 
Our research group demonstrated that the usefulness of aripi-
prazole in patients with schizophrenia included the improve-
ment of social competence,3 which refers to overall capacity 
to solve life problems and achieve instrumental and affiliative 
goals.4 These advantages of aripiprazole may be related to its 
distinctive pharmacological profile as a partial agonist of D2 
and HT1A receptors and as an antagonist of 5-HT2A and 5-HT2C 
receptors.5 This profile of aripiprazole is contrasted with th-
ose of other atypical antipsychotics; for example risperidone 
acts as a potent antagonist of both 5-HT2A and D2 receptors.6 
Although the relationship between aripiprazole and γ-amino-
butyric-acid (GABA) is not studied yet, the GABAergic me-
chanism may be also involved in the advantages of aripipra-
zole in that GABAergic neurotransmission closely interacts 
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with the dopamine and serotonin systems.7 
In fact, dysfunctional GABA transmission in the brain has 
been considered to play a role in the pathophysiology of schizo-
phrenia. For example, postmortem studies have reported up-
regulation of GABA receptor binding in the prefrontal cortex 
of patients with schizophrenia, whereas in vivo neuroimag-
ing studies using SPECT and [11C]Ro15-4513 PET have de-
monstrated that there is no difference in GABAA receptor bi-
nding between patients with schizophrenia and healthy con-
trols.7 Moreover, the GABA system is believed to be related 
to the mechanism responsible for the efficacy of antipsychotic 
medications.8,9 A previous pharmacoimaging study9 reported 
that typical and atypical antipsychotics had a different effect 
on regional GABA activities, but grouped together all atypi-
cal antipsychotics in one category and thus ignored a different 
mechanism of action or efficacy among the drugs. To our kn-
owledge, no studies have examined the difference of regional 
GABA receptor binding potential between patients taking aty-
pical antipsychotics. Therefore, further study deserves to be 
performed to clarify the effect on the GABA system by each 
of atypical antipsychotics including aripiprazole.
It should be considered here that GABAergic inhibition 
modulates cortical signal transduction operative in informa-
tion processing.7 If patients with schizophrenia who admin-
ister aripiprazole show a distinctive GABA-related change in 
some brain regions which are closely related to social func-
tions, it can be considered to be a neural basis of aripiprazole’s 
additional efficacy, especially on social competence.3 There are 
many brain structures that underlie social functions, which in-
cludes 1) prefrontal regions including the medial prefrontal 
cortex (MPFC), dorsolateral prefrontal cortex (DLPFC), fron-
topolar cortex (FPC), and premotor cortex, 2) temporoparietal 
regions including the temporal pole, superior temporal sulcus, 
temporoparietal junction and inferior parietal lobule, and 3) 
the amygdala.10-12 Taken together, we regarded these structu-
res as the a priori regions in the present study for investigating 
changes in GABAergic neurotransmission by aripiprazole.
This study was designed to examine a difference in GABAA 
receptor binding potential between long-term use of aripip-
razole and risperidone using [18F]-FFMZ PET imaging in re-
gions which were related to social functions. We hypothesiz-
ed that the GABAA receptor binding potentials in social com-




Seventeen patients with schizophrenia and 18 healthy con-
trols participated in this study. Inclusion criteria were an ex-
clusive diagnosis of schizophrenia in the patient group and 
the exclusion of any psychiatric disorder in the control group. 
Psychiatric diagnoses were assessed with the Structured Clini-
cal Interview for DSM-IV.13 Clinical symptoms of schizophre-
nia in the patient group were assessed using the Positive and 
Negative Syndrome Scale (PANSS).14 No participants reported 
any past or present history of significant medical or neurolo-
gical illness and drug or alcohol abuse. Patients and controls 
did not significantly differ in gender (eight males in the patient 
group, nine males in the control group), age (28.7±6.9 years and 
26.2±6.9 years, respectively), or years of education (14.0±1.6 
years and 13.7±1.5 years, respectively). The study was approv-
ed by the institutional review board and written informed con-
sent was obtained from all participants.
The patient group was divided into two subgroups accord-
ing to antipsychotic medication. Nine patients were taking 
aripiprazole monotherapy (mean dose: 17.8±9.4 mg) and eight 
patients were taking risperidone monotherapy (mean dose: 
3.4±2.4 mg). All patients and controls had not received ben-
zodiazepines for at least four weeks prior to the PET imaging 
session, but other medications were not restricted; two patients 
in the aripiprazole group reported current use of antidepres-
sants, six in the aripiprazole group and one in the risperidone 
group used propranolol, and six in the aripiprazole group and 
two in the risperidone group used anticholinergics. There was 
one left-handed patient in each subgroup. As shown in Table 
1, the aripiprazole, risperidone and control groups did not 
differ in gender, age and years of education. The two medica-
tion groups also did not differ in terms of duration of illness, 
duration of antipsychotics treatment, total and subscale scores 
of the PANSS, or mean chlorpromazine-equivalent dose of 
their antipsychotic medication. 
[18F]-FFMZ PET imaging
To investigate GABAA receptor binding potential, all sub-
jects were scanned using a GE Discovery STE PET/CT scan-
ner (GE, Milwaukee, WI, USA). A 10 min transmission CT 
scan was performed for attenuation correction. After injec-
tion of approximately 5.5 MBq (0.15 mCi)/kg of [18F]-FFMZ, 
a dynamic emission scan was performed in a sequence of 150 
frames in 3-D mode (60×10 s, 40×15 s, 20×30 s and 30×60 s) 
for a total acquisition time of 60 min. As described in our pre-
vious study using [18F]-FFMZ,15 actual emission data for statis-
tical analysis were obtained for 20 min in 20 min after injec-
tion of the radiotracer to avoid blood flow effects and non-
specific GABAA receptor binding. The attenuation-corrected 
emission data were reconstructed in a 128×128×47 matrix 
with a pixel size of 2.34×2.34×3.27 mm using Hanning and 
Ramp filters.
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Image preprocessing
Preprocessing and statistical analysis of [18F]-FFMZ PET 
images were performed using Statistical Parametric Mapping 
(SPM) software (SPM8, Institute of Neurology, University 
College London, UK). We first created a [18F]-FFMZ PET 
template using [18F]-FFMZ PET images and T1-weighted 
MR images of 20 healthy volunteers.15 All [18F]-FFMZ PET 
images obtained from patients and normal controls were spa-
tially normalized into the [18F]-FFMZ PET template to remove 
inter-subject anatomical variability. To calculate the GABAA 
receptor binding potential, we used a multi-linear reference 
tissue method.16 Given that the density of GABAA receptors 
in the pons is negligible, effect of global uptake was taken into 
account by normalizing the count of each voxel to the mean 
count within the pons. The GABAA receptor binding poten-
tial images were then smoothed by convolution with an isotro-
pic Gaussian kernel with a 14-mm.
Statistical analysis
A group comparison of GABAA receptor binding poten-
tials between all patients and healthy controls was performed 
by voxel-wise t-statistics at a threshold at uncorrected p<0.005 
with more than 20 contiguous voxels. A difference of GABAA 
receptor binding potentials among the aripiprazole, risperi-
done and control groups was evaluated by voxel-wise one-
way analysis of variance (ANOVA). An exploratory analysis 
for screening activations in the a priori regions was done at a 
threshold of uncorrected p<0.01 with more than 20 contigu-
ous voxels, and then the significant clusters in the a priori re-
gions were used for secondary small volume correction (SVC) 
analysis, which was conducted at family wise error (FWE)17-
corrected p<0.05 using 5-mm sphere with a fixation point at 
the local maxima. 
For post hoc analyses, the whole volumes of the clusters 
were defined as the regions of interest (ROIs), and the regio-
nal mean [18F]-FFMZ binding potentials of each subject were 
then tested for significance based on the ROIs using the indi-
vidual [18F]-FFMZ binding potential maps. Independent t-
tests for the ROI values were performed and Scheffé’s method 
was applied to correct for multiple comparisons.
RESULTS
As shown in Table 2, compared to the control group, [18F]-
FFMZ binding potential in the patient group was decreased 
in the subgenual cingulate cortex and left temporal pole, and 
increased in the right inferior occipital gyrus. As shown in 
Table 3 and Figure 1, a comparison of [18F]-FFMZ binding po-
tential among the aripiprazole, risperidone and control groups 
revealed significant differences in 4 prefrontal regions includ-
ing the right MPFC, left FPC, right DLPFC, and right premo-
tor cortex. A significant cluster was not found in other a priori 
regions such as the temporoparietal regions and amygdala.
Post hoc analyses revealed that [18F]-FFMZ binding poten-
tials in the right MPFC and the right DLPFC was significant-
ly lower in the aripiprazole group than the risperidone group, 
but they were not significantly different between the risperi-
done and control groups, or between the aripiprazole and con-
trol groups. [18F]-FFMZ binding potentials in the left FPC 
and the right premotor cortex were significantly lower in the 
aripiprazole group than the risperidone and control groups. 
Table 1. Comparison of clinical and demographic characteristics between the aripiprazole and risperidone groups
Aripiprazole group (N=9) Risperidone group (N=8) Control group (N=18) F/T/ χ2 p
Age (years) 27.3±5.0 30.1±8.7 26.2±6.9 0.88 0.43
Education (years) 13.9±1.8 14.1±1.6 13.7±1.5 0.25 0.79
Gender (M/F) 3/6 5/3 9/9 1.47* 0.48
Handedness (R/L) 8/1 7/1 18/0 2.26* 0.32
Dose of antipsychotics 
  (CP equivalence)
236.9±125.4 168.8±122.3 - 1.13 0.28
Duration of illness (years) 4.8±3.0 3.4±1.8 - 1.15 0.27
Duration of treatment (years)† 1.9±1.0 2.9±1.9 - -1.30 0.21
PANSS 
Positive 15.8±4.3 15.6±4.8 - 0.07 0.95
Negative 15.1±3.0 13.5±3.8 - 0.97 0.35
General 29.0±5.5 31.1±6.8 - -0.71 0.49
Total 61.0±9.5 60.3±14.1 - 0.13 0.90
Values are presented as means±standard deviation. *Pearson’s chi-square value, †duration of aripiprazole or risperidone was administered. 
CP: chlorpromazine, PANSS: Positive and Negative Syndrome Scale
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DISCUSSION
A comparison between the patient and control groups re-
vealed that [18F]-FFMZ binding potentials in the medicated 
patients were increased in the right inferior occipital gyrus, 
and decreased in the subgenual cingulate cortex and the left 
temporal pole. Given that increased GABAA receptor is con-
sidered an effect of an upregulation of the GABAA receptor 
complex due to presynaptic GABAergic deficiencies,7 regional 
increases of GABAA receptor binding potential may indicate 
decreased GABA transmission. Therefore, decreased GABAA 
receptor binding potential may be interpreted as increased 
GABA transmission and decreased regional brain activity. Sin-
ce the subgenual cingulate cortex and the temporal pole has 
been implicated in emotion regulation,18,19 decreased GABAA 
receptor binding potential in these regions may be related to 
emotional abnormality found in patients with schizophrenia. 
However, given that the patients in this study were medicated 
Table 3. Comparison of GABAA receptor binding potential among the aripiprazole (A), risperidone (R) and control (C) groups at a threshold 





Right medial prefrontal cortex (BA10) 36 2.52 8 58 2 A<R, A=C, R=C
Left frontopolar cortex (BA10) 32 2.52 -22 58 14 A=C<R
Right dorsolateral prefrontal cortex (BA46) 29 2.68 36 44 8 A<R, A=C, R=C
Right premotor cortex (BA6) 52 2.72 60 0 22 A<C=R
For post hoc analyses, the whole volumes of the clusters were defined as the regions of interest (ROIs), and the regional mean GABAA recep-
tor binding potentials of each subject were calculated based on the ROIs using the individual GABAA receptor binding potential maps. Group 
comparisons of the ROI values between the aripiprazole and risperidone groups, between the aripiprazole and control groups or between the 
risperidone and control groups were performed using independent t-tests. Scheffé’s method was applied to correct for multiple comparisons. 
Significance level for post hoc analyses was set at p<0.05. Nvox: number of voxels, Zmax: maximum Z value, MNI: Montreal Neurological In-
stitute, BA: Brodmann area
Figure 1. GABAA receptor binding potentials in the right medial prefrontal cortex (MPFC), the left frontopolar cortex (FPC), the right dorso-
lateral prefrontal cortex (DLPFC) and the premotor cortex (PMC) were significantly lower in the aripiprazole group than the risperidone 





Table 2. Decreased or increased GABAA receptor binding potential in the patient group when compared with the control group at a thresh-




Decreases in the patient group
Subgenual cingulate cortex (BA25) 106 2.90 2 8 -4
Left temporal pole (BA38) 23 2.75 -46 18 -12
Increases in the patient group
Right inferior occipital gyrus (BA19) 80 2.76 38 -74 -4
Nvox: number of voxels, Zmax: maximum Z value, MNI: Montreal Neurological Institute, BA: Brodmann area
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for a long time, our findings of regional differences of GAB-
AA receptor binding potential might also reflect an effect of 
medication or deterioration after long duration of illness.
In a comparison among the three groups, the aripiprazole 
group showed significantly decreased [18F]-FFMZ binding 
potentials in the right MPFC, left FPC and right DLPFC com-
pared to the risperidone group, suggesting increased prefron-
tal GABA transmission due to aripiprazole. Since appropriate 
GABAergic inhibition in the prefrontal cortex is essential for 
information processing,20 increased prefrontal GABA transmi-
ssion can be interpreted as increased functional activity. The 
MPFC is one of the principal components of social brain,10,11 
brain regions specialized for social cognition. The MPFC in-
tegrates social information across time, allows reflection and 
representation of traits and norms,21 and is also involved in 
theory of mind and mentalizing.11 The FPC acts as a modu-
lator of social cognition by overriding ongoing processing to 
explore new options.22 In addition, the DLPFC is thought to 
contribute to cognitive control in social situations by maintain-
ing understanding of one person’s intentions and evaluating 
whether a second person’s actions appear consistent with those 
intentions.23 Collectively, the effect of increased prefrontal 
GABA transmission may have possible contribution to aripip-
razole’s social competence improvement.
Both the aripiprazole and risperidone groups showed no 
significant difference in [18F]-FFMZ binding potentials in the 
right MPFC and right DLPFC compared to the control group. 
The functional and structural abnormalities in the MPFC and 
DLPFC have been consistently reported in patients with schi-
zophrenia.24,25 Moreover, recent studies found elevated GABA 
levels in the MPFC in unmedicated patients26 and altered GA-
BA receptor subunit in the DLPFC in patients regardless of me-
dication use.27 Comparable levels of GABAA receptor binding 
potentials in the MPFC and DLPFC suggest that aripiprazole 
and risperidone administration may possibly normalize 
GABA alterations in patients with schizophrenia. However, 
future studies with drug naïve patients using [18F]-FFMZ PET 
should be warranted because comparable levels of GABAA 
receptor binding potentials might be due to decreased sensiti-
vity of [18F]-FFMZ PET imaging. 
Compared to both the risperidone and control groups, the 
aripiprazole group showed decreased [18F]-FFMZ binding 
potential in the right premotor cortex, which indicates incre-
ases in GABA transmission in the premotor area by aripipra-
zole. Because GABA inhibits the function of the premotor cor-
tex,28 this finding of increased premotor GABA transmission 
in the aripiprazole group suggests decreased premotor func-
tioning. The premotor cortex forms the core of the mirror-
neuron system which estimates the mental state of the other 
person in a social interaction11 and decreased premotor fun-
ctioning could be opposite of our hypothesis. However, pa-
tients with Parkinson’s disease show increased activity in the 
premotor cortex compared to healthy controls,29 and this hy-
peractivation in the premotor cortex decreases after pharma-
cologic treatment.30 Therefore, decreased premotor function-
ing may be related to less liability for neuroleptic induced 
parkinsonism found in aripiprazole compared with risperi-
done.5 Since social functioning can be negatively influenced 
by parkinsonism,31 decreased premotor activity may be also 
possibly linked to social competence improvement by aripip-
razole. But it is hard to interpret that the aripiprazole group 
had decreased premotor functioning compared to the con-
trol group. Decreased premotor functioning may be a com-
pensatory mechanism for antipsychotic induced parkinso-
nian symptoms; however, future controlled studies are needed.
The present study has several limitations, most of which stem-
med from an open, naturalistic design of the present study in 
an outpatient clinic for chronic patients. First, there was a risk 
of selection bias because the medication groups were not ran-
domly assigned. Second, the sample size of each group was 
small. Third, the gender ratio in the aripiprazole and risperi-
done groups was not matched. Fourth, measures of social com-
petence, parkinsonian symptoms and smoking history were 
not administered. Most of all, we used brain areas instead of 
behavioral measures about social competence to explain the 
relationship between aripiprazole administration and social 
competence improvement. Therefore, future randomized 
controlled studies including extensive measures are needed 
for more precise conclusions about the relation between me-
dication and behavioral functioning.
In conclusion, administration of aripiprazole resulted in 
changes in prefrontal GABA transmission, including incre-
ases in the MPFC, FPC, DLPFC and premotor regions. In that 
these regions have been reported to be involved in various so-
cial functions, social competence improvement would be one 
of the possible reasons for GABAA receptor changes. Despite 
limitations, our preliminary study contributes meaningful 
data as to how the GABA system may be associated with cli-
nical advantages of aripiprazole.
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